BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28260402)

  • 1. Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer.
    Jackman DM; Zhang Y; Dalby C; Nguyen T; Nagle J; Lydon CA; Rabin MS; McNiff KK; Fraile B; Jacobson JO
    J Oncol Pract; 2017 Apr; 13(4):e346-e352. PubMed ID: 28260402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
    Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
    Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An economic analysis of sublobar resection versus thermal ablation for early-stage non-small-cell lung cancer.
    Kwan SW; Mortell KE; Hippe DS; Brunner MC
    J Vasc Interv Radiol; 2014 Oct; 25(10):1558-64; quiz 1565. PubMed ID: 25130308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does timeliness of care in Non-Small Cell Lung Cancer impact on survival?
    Vinod SK; Chandra A; Berthelsen A; Descallar J
    Lung Cancer; 2017 Oct; 112():16-24. PubMed ID: 29191589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
    Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF
    Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.
    Boros A; Lacroix L; Lacas B; Adam J; Pignon JP; Caramella C; Planchard D; de Montpreville V; Deutsch E; Levy A; Besse B; Le Pechoux C
    Oncotarget; 2017 Apr; 8(15):25189-25199. PubMed ID: 28445990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy.
    Lee H; Jin GY; Han YM; Chung GH; Lee YC; Kwon KS; Lynch D
    Cardiovasc Intervent Radiol; 2012 Apr; 35(2):343-50. PubMed ID: 21626257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Br J Cancer; 1995 Nov; 72(5):1270-7. PubMed ID: 7577481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic non-small cell lung cancer: costs associated with disease progression.
    Fox KM; Brooks JM; Kim J
    Am J Manag Care; 2008 Sep; 14(9):565-71. PubMed ID: 18778171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease.
    Deepak JA; Ng X; Feliciano J; Mao L; Davidoff AJ
    Ann Am Thorac Soc; 2015 May; 12(5):742-51. PubMed ID: 25760983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): a California Cancer Registry analysis.
    Lara MS; Brunson A; Wun T; Tomlinson B; Qi L; Cress R; Gandara DR; Kelly K
    Lung Cancer; 2014 Aug; 85(2):264-9. PubMed ID: 24878033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of care and outcomes for stage IIIB non-small cell lung cancer in the TNM-7 era: Results from the Netherlands Cancer Registry.
    Dickhoff C; Dahele M; Smit EF; Paul MA; Senan S; Hartemink KJ; Damhuis RA
    Lung Cancer; 2017 Aug; 110():14-18. PubMed ID: 28676212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.
    Rodrigues G; Oberije C; Senan S; Tsujino K; Wiersma T; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; DeRuyck K; De Dios NR; Warner A; Bradley JD; Palma DA
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):133-9. PubMed ID: 25835622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis.
    Puri V; Crabtree TD; Kymes S; Gregory M; Bell J; Bradley JD; Robinson C; Patterson GA; Kreisel D; Krupnick AS; Meyers BF
    J Thorac Cardiovasc Surg; 2012 Feb; 143(2):428-36. PubMed ID: 22169443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and function.
    Dickhoff C; Hartemink KJ; van de Ven PM; van Reij EJ; Senan S; Paul MA; Smit EF; Dahele M
    Lung Cancer; 2014 Aug; 85(2):218-23. PubMed ID: 24976333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in treatment and relative survival among Non-Small Cell Lung Cancer patients in the Netherlands (1990-2014): Disparities between younger and older patients.
    Driessen EJ; Aarts MJ; Bootsma GP; van Loon JG; Janssen-Heijnen ML
    Lung Cancer; 2017 Jun; 108():198-204. PubMed ID: 28625635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissecting the heterogeneity of stage III non-small-cell lung cancer through incorporation of grade and histology.
    Abdel-Rahman O
    Future Oncol; 2017 Dec; 13(30):2811-2821. PubMed ID: 29188724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.
    Skinner KE; Fernandes AW; Walker MS; Pavilack M; VanderWalde A
    J Med Econ; 2018 Feb; 21(2):192-200. PubMed ID: 29041833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
    Vinod SK; Wai E; Alexander C; Tyldesley S; Murray N
    J Thorac Oncol; 2012 Jul; 7(7):1155-63. PubMed ID: 22617240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Survival after Salvage Surgery for Local Failure after Definitive Chemoradiation Therapy for Locally Advanced Non-small Cell Lung Cancer.
    Schreiner W; Dudek W; Lettmaier S; Fietkau R; Sirbu H
    Thorac Cardiovasc Surg; 2018 Mar; 66(2):135-141. PubMed ID: 28992654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.